Slingshot members are tracking this event:

Agios Pharma (AGIO) to complete Phase 1/2 Study of AG-221 in Subjects with Hematologic Malignancies with an IDH2 Mutation in September 2017

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks



Additional Information

Additional Relevant Details An ongoing Phase 1 trial that includes a dose-escalation phase, four expansion cohorts of 25 patients each and a Phase 2 expansion cohort of 125 patients with IDH2 mutant-positive AML who are in second or later relapse, refractory to second-line induction or reinduction treatment, or have relapsed after allogeneic transplantation. The primary objectives of the study are to confirm the safety and clinical activity of AG-221 in a select, highly resistant AML population
Slingshot Insights Explained
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Phase 1/2 Study, Ag-221, Hematologic Malignancies, Idh2 Mutation, Open Label